

CERTIFICATE

Survey of 28 June 2024

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Virus Genome Detection - Human Papilloma Viruses (373):

Validity 12 months:

Differentiation of "High Risk" and "Low Risk" types of HPV (R: B3)

Detection of "High Risk" HPV (without detection of "Low Risk" HPV) (R: B3)

Typing of "High Risk" HPV and "Low Risk" HPV (R: B3)

(R) analysis is subject to the RiliBÄK

Customer:
10041629
Medyczne Laboratoria Diagnostyczne
INVICTA Sp. z o.o.
Polna 64
81-740 Sopot

Düsseldorf, 30 July 2024



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Dr. Steffi Silling
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 28 June 2024

You have participated in the External Quality Assessment with the following analysis

Virus Genome Detection - Human Papilloma Viruses (373):

Differentiation of "High Risk" and "Low Risk" types of HPV (R: B3)

Detection of "High Risk" HPV (without detection of "Low Risk" HPV) (R: B3)

Typing of "High Risk" HPV and "Low Risk" HPV (R: B3)

(R) analysis is subject to the RiliBÄK

Customer:
10041629
Medyczne Laboratoria Diagnostyczne
INVICTA Sp. z o.o.
Polna 64
81-740 Sopot

Düsseldorf, 30 July 2024



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Dr. Steffi Silling
(Adviser)